Researchers Identify SRPX2 as Colorectal Cancer Driver
A newly identified protein pathway could provide a target for treating aggressive, immunotherapy-resistant tumors.
Updated on Oct. 15, 2026 in Cancer
Scientists have discovered that the protein SRPX2 acts as a primary driver of metastasis in colorectal cancer. By stabilizing TGFBR2, this protein activates the TGF-beta signaling pathway, which encourages aggressive tumor growth and spread.
Why it matters
High levels of SRPX2 are linked to increased resistance against immunotherapy, limiting treatment options for patients with advanced colorectal cancer. Understanding this mechanism offers a potential new avenue for therapeutic intervention in resistant cases.
The study demonstrates that SRPX2 stabilizes TGFBR2 to promote epithelial-mesenchymal transition and extracellular matrix remodeling. Data confirms that targeting this axis enhances immune checkpoint inhibitor sensitivity in models.
The details
The research reveals that SRPX2 facilitates the progression of colorectal cancer by reprogramming the extracellular matrix and promoting epithelial-mesenchymal transition. These biological changes directly correlate with more aggressive disease progression and reduced efficacy of current immune therapies.
Timeline
October 15, 2026: The research findings were formally published.
The Big Picture
This discovery updates the scientific model of the TGF-beta signaling pathway by identifying a previously unknown regulator. It challenges legacy understandings of how protein stabilization impacts the overall aggressiveness of metastatic colorectal tumors.
This research provides a foundational target that may one day lead to more effective therapies for patients currently showing resistance to immune checkpoint inhibitors. While not a current clinical treatment, the identification of the SRPX2 axis may eventually guide future drug development.
The takeaway
Targeting the SRPX2 protein may overcome resistance to standard immunotherapies in specific colorectal cancer patients. Future research will focus on developing inhibitors that can safely block this pathway in human subjects.
Further reading
Find more breakthroughs in oncology research on our Cancer page.
More information
Read the full details in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
